Bio-Techne Q2 revenue flat at $295.9M; adjusted EPS rises to $0.46 from $0.42

BIO-TECHNE Corp

2026-Q2 EPS reported $0.49 revenue$582,432,000

GAAP EPS of $0.24 vs $0.22; adjusted EPS of $0.46 vs $0.42, both year-over-year increases.
Protein Sciences segment revenue +2% to $215.1M; operating margin fell to 39.3% from 41.2%.
Diagnostics & Spatial Biology segment revenue -4% to $81.2M; organic growth +3% with margin up to 10.4%.
Board declares $0.08/share quarterly dividend, payable Feb 27, 2026 to holders of record Feb 16, 2026.
China/APAC region drove growth for third consecutive quarter; large pharma end-market grew double digits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.